Literature DB >> 12005404

Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.

Rüdiger Gerlach1, Gerhard Marquardt, Heimo Wissing, Inge Scharrer, Andreas Raabe, Volker Seifert.   

Abstract

The authors report on a 64-year-old woman with a huge recurrent skull base hemangiopericytoma, in whom they encountered severe difficulty in attaining intraoperative hemostasis. Standard surgical hemostatic methods and the administration of fresh-frozen plasma and prothrombin complex concentrates failed to stop diffuse bleeding from an inoperable tumor remnant. At a critical point during the operation, the intravenous administration of recombinant activated factor VII, combined with mechanical compression, finally led to satisfactory hemostasis. The rationale for using recombinant activated factor VII in situations of uncontrolled bleeding during neurosurgical procedures is discussed, along with the literature in which the use of recombinant activated factor VII as a maneuver of last resort is reported for hemostasis in other surgical fields.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005404     DOI: 10.3171/jns.2002.96.5.0946

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

Review 1.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 2.  Management of coagulopathy in the setting of acute neurosurgical disease and injury.

Authors:  Marlon Mathews; Richard Newman; E Thomas Chappell
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 3.  Pharmacology and clinical use of recombinant activated factor seven in neurosciences.

Authors:  Matthias Hartmann; Christoph Sucker
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

Review 4.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

5.  Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.

Authors:  Jean-Louis Vincent; Rolf Rossaint; Bruno Riou; Yves Ozier; David Zideman; Donat R Spahn
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

6.  Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial.

Authors:  Yoram Kluger; Bruno Riou; Rolf Rossaint; Sandro B Rizoli; Kenneth David Boffard; Philip Iau Tsau Choong; Brian Warren; Michael Tillinger
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.